Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3451644 | 0.87 | PRKCI (0.49) | CNR2PRKCIFFAR1HTR7ACMSD | |
| SCHEMBL1508340 | 0.87 | HTR7 (0.59) | CNR2PRKCIFFAR1HTR7NR1H2 | |
| SCHEMBL28011375 | 0.87 | FGFR1 (0.49) | CNR2PRKCIFFAR1HTR7ACMSD | |
| SCHEMBL12577786 | 0.84 | FFAR1 (0.59) | FFAR1 | |
| SCHEMBL28011376 | 0.81 | CNR2 (0.48) | CNR2PRKCIFFAR1HTR7ACMSD | |
| SCHEMBL204013 | 0.81 | CNR2 (0.42) | CNR2FFAR1ACMSDHSD17B1HSD17B2 | |
| SCHEMBL12640964 | 0.80 | CYP11B1 (0.43) | CNR2PRKCIFFAR1HTR7NR1H2 | |
| SCHEMBL12577779 | 0.80 | PRKCI (0.42) | CNR2PRKCIFFAR1HTR7ACMSD | |
| SCHEMBL3450142 | 0.80 | FFAR1 (0.65) | FFAR1 | |
| SCHEMBL12577791 | 0.79 | HTR7 (0.51) | CNR2PRKCIFFAR1HTR7NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2803664-B1 | TETRAHYDROBENZOFURANE DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF DIABETES | JIANGSU HENGRUI MEDICINE CO (CN) | 2018-11-21 | — | — | EP | disclosed |
| US-20160200734-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | KANG, XINSHAN (CN) | 2016-07-14 | — | — | US | disclosed |
| US-20160200734-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | KANG, XINSHAN (CN) | 2016-07-14 | — | — | US | disclosed |
| US-9139548-B2 | Polycyclic derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2015-09-22 | — | — | US | disclosed |
| WO-2015062486-A1 | BIPHENYL COMPOUNDS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-05-07 | — | — | WO | disclosed |
| WO-2015062486-A1 | BIPHENYL COMPOUNDS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-05-07 | — | — | WO | disclosed |
| WO-2015028960-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS GPR AGONISTS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2015-03-05 | — | — | WO | disclosed |
| US-20150005282-A1 | POLYCYCLIC DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2015-01-01 | — | — | US | disclosed |
| EP-2803664-A1 | POLYCYCLIC DERIVATIVES, PREPARATION METHOD AND MEDICAL USES THEREOF | Jiangsu Hengrui Medicine Co. Ltd. (CN) | 2014-11-19 | — | — | EP | disclosed |
| EP-2743268-A2 | Fused cyclic compounds as GPR40 receptor modulators | Takeda Pharmaceutical Company Limited (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-20100197761-A1 | Fused cyclic compounds | YASUMA TSUNEO | 2010-08-05 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7732626-B2 | Fused cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20090186909-A1 | Oxadiazolidinedione Compound | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-2041123-A2 | FUSED CYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008001931-A2 | FUSED CYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200734-A1 | CARBOXYLIC ACID COMPOUNDS IN TREATMENT OF DIABETES MELLITUS | GPR119, GLP1R, INSR | CNR2 440/4885PRKCI 2704/4885FFAR1 9/4885 |
| US-20100004312-A1 | FUSED CYCLIC COMPOUNDS | GPR119, GLP1R, GPR65 | CNR2 402/4885PRKCI 2231/4885FFAR1 15/4885 |
| US-20090186909-A1 | Oxadiazolidinedione Compound | GPR119, GPR39, GPR65 | CNR2 937/4885PRKCI 2686/4885FFAR1 64/4885 |
| US-20100197761-A1 | Fused cyclic compounds | GPR119, GLP1R, GPR65 | CNR2 402/4885PRKCI 2231/4885FFAR1 15/4885 |
| US-20150005282-A1 | POLYCYCLIC DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | GPR119, GPR55, GPR65 | CNR2 79/4885PRKCI 2424/4885FFAR1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.